• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    40.46 -0.06 (-0.15%)
    Official Closing Price Updated: 7:00 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,485,448
    Open 40.51
    Bid (Size) 40.98 (1,200)
    Ask (Size) 41.00 (100)
    Prev. Close 40.52
    Today's Range 40.26 - 40.85
    52wk Range 35.12 - 81.44
    Shares Outstanding N/A
    Dividend Yield 2.89%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Here's Why Agios Pharmaceuticals Crashed 23% Today ↗
    The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow. 
    Via The Motley Fool
    News headline image
    This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗
    Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock. 
    Via The Motley Fool
    Topics Intellectual Property Stocks

    Performance

    YTD
    -22.8%
    -22.8%
    1 Month
    +10.8%
    +10.8%
    3 Month
    -33.3%
    -33.3%
    6 Month
    -27.4%
    -27.4%
    1 Year
    -30.6%
    -30.6%

    More News

    Read More
    News headline image
    3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗
    Via MarketBeat
    News headline image
    Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗
    Via The Motley Fool
    News headline image
    Should You Forget CVS Health and Invest in a Purer Healthcare Play? ↗
    Via The Motley Fool
    News headline image
    Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market ↗
    Via The Motley Fool
    News headline image
    The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust ↗
    Via The Motley Fool
    News headline image
    Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
    Via The Motley Fool
    News headline image
    The Global Pantry Reimagined: Unilever and McCormick Seal $65 Billion Merger Deal
    Via MarketMinute
    Topics Economy Supply Chain
    News headline image
    The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
    Via MarketMinute
    News headline image
    Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker? ↗
    Via The Motley Fool
    News headline image
    3 Absurdly Cheap Dividend Stocks to Buy in April 2026 ↗
    Via The Motley Fool
    Topics Economy
    News headline image
    Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
    Via MarketMinute
    Topics Artificial Intelligence
    News headline image
    Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market
    Via MarketMinute
    Topics Artificial Intelligence Economy Initial Public Offering
    News headline image
    The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
    Via MarketMinute
    Topics Economy World Trade
    News headline image
    Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals? ↗
    Via MarketBeat
    News headline image
    Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight ↗
    Via The Motley Fool
    News headline image
    Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%
    Via MarketMinute
    Topics Artificial Intelligence Economy Stocks
    News headline image
    Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗
    Via The Motley Fool
    News headline image
    The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
    Via MarketMinute
    Topics Economy
    News headline image
    The Evolution of The Cigna Group: A Deep Dive into a Health Services Powerhouse (2026)
    Via Finterra
    Topics Artificial Intelligence Economy Lawsuit
    News headline image
    The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Why Eli Lilly Stock Trounced the Market Today ↗
    Via The Motley Fool
    News headline image
    Eli Lilly’s $47.8 Billion Masterstroke: The Contessa Acquisition and the New Era of Pharmaceutical Dominance
    Via MarketMinute
    Topics Artificial Intelligence Economy

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 40.46
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 04/20/26 07:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.